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Eﬀect of Physiological Determinants and Cardiac Disease on
Plasma Adiponectin Concentrations in Dogs
C. Damoiseaux, A.-C. Merveille, E. Kraﬀt, A.M. Da Costa, S. Gomart, P. Jespers, C. Michaux, C.
Clercx, C. Verhoeven, and K. Mc Entee
Background: In humans, a high concentration of adiponectin is associated with a favorable cardiovascular risk
proﬁle whereas, in patients with heart failure (HF), a high concentration of adiponectin is associated with a less favorable
prognosis.
Hypothesis/Objectives: To evaluate the physiological determinants of plasma adiponectin concentration in dogs and the
inﬂuence of heart disease, myxomatous mitral valve disease (MMVD), and dilated cardiomyopathy (DCM).
Animals: One hundred and fourteen client-owned dogs and 9 Beagles from the research colony of the Clinical Veteri-
nary Unit of the University of Liege.
Methods: We prospectively measured circulating adiponectin concentration in healthy control dogs (n = 77), dogs with
MMVD (n = 22) and dogs with DCM (n = 15) of various degrees of severity. Diagnosis was conﬁrmed by Doppler echo-
cardiography. Plasma adiponectin concentration was measured by a canine-speciﬁc sandwich ELISA kit.
Results: An analysis of covariance showed an association between adiponectin concentration and age, neuter status,
and heart disease. No association between adiponectin concentration and class of HF, sex, body condition score, body
weight, circadian rhythm, or feeding was found. Plasma adiponectin concentration was negatively correlated with age
(P = .001). Adiponectin was lower in neutered (P = .008) compared to intact dogs. Circulating adiponectin concentration
was increased in dogs with DCM compared to healthy dogs (P = .018) and to dogs with MMVD (P = .014).
Conclusions and Clinical Importance: Age and neutering negatively inﬂuence circulating adiponectin concentration.
Plasma adiponectin concentration increased in dogs with DCM. Additional research is required to investigate if this hor-
mone is implicated in the pathophysiology of DCM and associated with clinical outcome.
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White adipose tissue, especially visceral fat, isbecoming regarded as an important endocrine
organ that secretes a wide variety of hormones, cytokines,
and growth factors, collectively labeled adipokines.1
Adiponectin is the most abundant circulating adipoki-
ne, exerting insulin-sensitizing, anti-inﬂammatory and
anti-atherosclerotic eﬀects.2 Adiponectin is cardiopro-
tective, promoting myocardial availability of free fatty
acids, glucose,3,4 and cardiomyocyte survival.5
In humans, although adipocytes are responsible for its
secretion, plasma adiponectin concentration decreases
with increased fat mass, especially with visceral fat distri-
bution in relation with to metabolic syndrome.6 More-
over, in healthy individuals, high plasma adiponectin
concentrations are associated with a low cardiovascular
risk proﬁle7 whereas, in patients with existing heart
failure (HF), high concentrations of this hormone are
paradoxically associated with worse outcome.8,9
In dogs, the inverse relationship between adiponec-
tin and adiposity is highly controversial, with discrep-
ant conclusions resulting perhaps from confounding
factors such as sex or neuter status.10 These observa-
tions raise the possibility that the physiology of adipo-
nectin is diﬀerent in dogs compared to humans.11
Moreover, to the best of our knowledge, no informa-
tion regarding circulating adiponectin concentrations
in dogs with HF is available. Cardiac diseases leading
to HF diﬀer among species. HF in humans is mostly
secondary to myocardial ischemia whereas in dogs HF
is mostly secondary to primary myocardial disease or
valve degeneration. Therefore, the implication of
adiponectin in the pathophysiology and prognosis of
heart diseases also may be diﬀerent.
Therefore, this study was intended to evaluate physi-
ological determinants of circulating adiponectin con-
centration such as circadian rhythm, age, sex, neuter
status, body weight (BW), and body condition score
(BCS). Taking these determinants into account, we
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investigated plasma adiponectin concentrations in dogs
at diﬀerent stages of myxomatous mitral valve disease
(MMVD) or dilated cardiomyopathy (DCM).
Material and Methods
The study protocol was approved by the Committee on Ani-
mal Experimentation of the University of Liege. Care of experi-
mental animals conformed to the “Guide for the Care and Use
of Laboratory Animals” (NIH publication no. 85-23, National
Academy Press, Washington, DC, revised 1996).
Dogs
Healthy control dogs and dogs with heart disease were pro-
spectively recruited from the Clinical Veterinary Unit of the Uni-
versity of Liege. Nine Beagle dogs, belonging to the dog colony of
the Clinical Veterinary Unit and fed once daily at 11 AM with a
maintenance dry diet, were used in a substudy to investigate the
eﬀects of feeding and circadian rhythm. Breed, age, sex, neuter
status, BW, and BCS (on a 5-point scale) were noted for each
dog. Dogs were considered healthy if they did not have any his-
tory of clinical disease with systemic repercussions and had nor-
mal physical examination ﬁndings. Additional diagnostic tests to
establish their state of health were not carried out. In dogs with
cardiac disease, diagnosis and assignment to class of HF were
made on the basis of history, clinical signs and consistent results
of physical examination, thoracic radiography, ECG, and Dopp-
ler echocardiography. Standard echocardiography and conven-
tional Doppler examinations were performed by trained observers
(1 resident in cardiology or 1 board-certiﬁed cardiologist). All
measurements were made by 1 board-certiﬁed cardiologist. A
right parasternal window was used to record 2-dimensional and
M-mode images in the long and short axes. Left ventricular vol-
umes and ejection fraction were calculated by the Simpson’s
method. The left atrial/aortic diameter ratio was obtained at end-
systole from the 2-dimensional short axis view at the level of the
aorta. Diagnosis of MMVD was based on remodeling of mitral
valve leaﬂets, mitral valve prolapse, and the presence of a systolic
regurgitation jet. Dilated cardiomyopathy was diagnosed using
published guidelines.12 Dogs with any other cardiac disease or
clinically relevant organ-related or systemic disease were not
enrolled. Dogs with heart disease then were classiﬁed in HF class
I, II, or III according to the International Small Animal Cardiac
Health Council (ISACHC) classiﬁcation system.13
Assay
For each dog, a 2 mL blood sample was collected by jugular
puncture into an EDTA-containing tube. To test diurnal varia-
tion and eﬀect of feeding, repeated samples were taken every
6 hours during 24 hours in 9 Beagles. Plasma was separated by
centrifugation (10 minutes 1,200 9 g at room temperature)
within 30 minutes of collection, transferred to cryotubes and fro-
zen at 80°C until assay. Plasma adiponectin concentration was
measured in duplicate by a canine-speciﬁc sandwich ELISA kita
according to the manufacturer’s instructions. The use of this
assay has been reported previously for canine samples.14 The
intra-assay and inter-assay coeﬃcients of variation were 4.1 and
4.4%, respectively.
Statistical Analysis
Statistical analysis was performed using the software IBM
SPSS 22 and R with the “compute.es” package. Statistical signiﬁ-
cance was set at P < .05. Normality was tested using the Shap-
iro–Wilk test. Nonnormally distributed variables were log
transformed for analysis or analyzed using nonparametric
methods.
Demographic characteristics of control dogs, dogs with
MMVD and dogs with DCM were compared using a one-way
analysis of variance or a Kruskall–Wallis test for continuous vari-
ables and a chi-square test for dichotomous variables. The circa-
dian rhythm eﬀect of the adiponectin concentrations was tested by
one-way analysis of variance for repeated measurements. For the
analyses thereafter, adiponectin concentrations were log trans-
formed. In healthy dogs, inﬂuence on adiponectin concentration
of age and BW covariates and of the categorical eﬀects of sex,
neuter status and BCS as well as the homogeneity of slopes
between the levels of the categorical eﬀects were tested by an
analysis of covariance. We performed a second analysis including
dogs with heart disease (MMVD and DCM) and adding the cate-
gorical eﬀects of cardiac status (healthy, MMVD, DCM) and clas-
ses of HF (healthy, ISACHC I, II, and III). Thereafter, the
adjusted means of the categorical eﬀects as well as their 95% CI
were back-transformed. To provide standard concentrations of
adiponectin according to age in healthy dogs, 3 regressions on age
(all of the healthy dogs, intact, and neutered dogs) of the adipo-
nectin concentration were calculated, as well as the 95% CI for
the mean of the predicted concentrations. For signiﬁcant categori-
cal eﬀects, a multiple comparison test on the pairwise adjusted
means was performed using the Sidak adjustment method.
When the comparison gave a statistically signiﬁcant diﬀerence, the
Cohen’s d eﬀect size was calculated. This is deﬁned as the diﬀer-
ence between 2 means divided by a standard deviation, and there-
fore the magnitude of Cohen’s d gives a normalized measure of
the importance of a statistically signiﬁcant variable.15 Finally, in
dogs with heart disease, any relationship between echocardio-
graphic indices (ejection fraction, fractional shortening, left atrial
diameter/aortic diameter ratio, left ventricular systolic volume
index, left ventricular diastolic volume index), and plasma adipo-
nectin concentration was tested by an analysis of covariance.
Results
Study Population
Demographic characteristics of healthy and cardiac
dogs included in the study are described in Table 1.
Dogs with heart disease were grouped as HF ISACHC
I (n = 14), ISACHC II (n = 15) and ISACHC III
(n = 8). Twenty-two dogs were diagnosed with MMVD
and 15 dogs with DCM. In healthy dogs, the most fre-
quently represented breeds were as follows: English
Sheepdog (n = 10), followed by Beagle (n = 8), cross-
bred (n = 6), and French Bulldog (n = 4). In the
MMVD group, the most frequently represented breeds
were Bichon (n = 5), crossbred (n = 5), and Cavalier
King Charles Spaniel (n = 2). In the DCM group, giant
and large breeds were most frequently represented,
including Labrador (n = 4) and Great Dane (n = 3).
A greater proportion (P = .016) of the female popu-
lation was neutered (43%) than the male population
(20%). No signiﬁcant diﬀerence in the sex ratio and in
the percentage of neutered dogs was seen between
healthy dogs and dogs with heart disease.
Dogs with MMVD (11.0  3.8 years old, [mean 
SD]) were older than healthy dogs (4.5  3.7 years
old, P < .001) and dogs with DCM (7.6  2.5 years
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old, P = .005), whereas dogs with DCM were older
than healthy dogs (P = .002).
Dogs with MMVD had a lower BW (6.4 [5.4–
11.2] kg, median [interquartile range] than healthy
dogs (14.7 [11.0–29.8] kg, P = .002) and dogs with
DCM (33.0 [28.4–39.0] kg, P = .007). Dogs with DCM
were heavier than healthy dogs (P = .005).
Echocardiographic characteristics of all dogs with
heart disease are summarized in Table 2. Because these
variables were used to construct the groups, we did
not compare the groups statistically. Twenty-nine of
37 dogs with heart disease (MMVD or DCM) were
already under treatment at inclusion. At inclusion, 33
dogs were being managed in the home environment
and 4 dogs in DCM ISACHC class III were hospital-
ized for stabilization.
Plasma Adiponectin Concentration in Healthy Dogs
A preliminary analysis showed no signiﬁcant eﬀect
of sex, BCS or BW on adiponectin concentration. It
also showed that the coeﬃcient of regression on age
was not signiﬁcantly diﬀerent between intact and neu-
tered dogs. The ANCOVA analysis showed that adipo-
nenctin concentration was signiﬁcantly inﬂuenced by
age (P = .001) and neutering (P = .008). The adjusted
geometric means and 95% CI are given for neutered
and intact dogs in Table 3. Cohen’s d eﬀect size was
calculated on adjusted means from the log of adipo-
nectin concentration for neutered and intact dogs.
After the standard of Cohen15 (|d| < 0.2: no practical
eﬀect, 0.2 < |d| < 0.5: small eﬀect, 0.5 < |d| < 0.8: med-
ium eﬀect, |d| > 0.8: large eﬀect), neutering had a med-
ium eﬀect on adiponectin concentration. Values for d
and its 95% CI are given in Table 3. No signiﬁcant
diﬀerence in plasma adiponectin concentration was
observed between males and females but neutering led
to lower plasma adiponectin concentration that was
signiﬁcant in females (Fig 1). Average adiponectin ref-
erence concentrations in units according to age are
presented for all healthy dogs (Fig 2A) and separately
for healthy intact (Fig 2B) and neutered (Fig 2C)
dogs. In a substudy using 9 Beagles, a signiﬁcant diur-
nal or feeding eﬀect on plasma adiponectin concentra-
tion was not observed (Fig 3).
Plasma Adiponectin Concentration in HF Dogs
Versus Control Dogs
When control and heart disease dogs were included
in the analysis, plasma adiponectin concentration was
signiﬁcantly inﬂuenced by neuter status (P < .001),
age (P = .014), and heart disease (P = .007). The
corresponding adjusted geometric means and their
95% conﬁdence limits are given in Table 4. Age nega-
tively inﬂuenced adiponectin concentration without
Table 1. Distribution of dogs included in the study.
Variable Beagles Healthy
Heart Disease
ISACHC I ISACHC II ISACHC III
Number 9 77 14 15 8
Male/female 3/6 36/41 11/3 7/8 6/2
Neutered (%) 0 30 29 53 0
Age (years) 7.6  3.6 4.5  3.5 9.5  4.1 10.8  2.7 7.7  3.1
BW (kg) 14.2  1.5 20  8.8 14  11.2 22  19.4 22  11.3
BCS (1/2/3/4/5) 0/0/7/2/0 2/8/45/12/10 0/4/6/4/0 1/4/3/7/0 0/4/2/2/0
MMVD 11 8 3
DCM 3 7 5
Values are expressed as mean  SD. BW, body weight; BCS, body condition score (from 1 to 5); MMVD, myxomatous mitral valve
disease; DCM, dilated cardiomyopathy; ISACHC, International Small Animal Cardiac Health Council.




All (n = 15) I (n = 3) II (n = 7) III (n = 5) All (n = 22) I (n = 11) II (n = 8) III (n = 3)
LA/Ao 2.1  0.4 1.6  0.5 2.1  2.6 2.3  0.2 2.0  0.9 1.6  0.3 2.5  0.6 2.2  0.9
LVVId (mL/m2) 121  39 85  43 135  3 126  29 70  38 55  33 88  31 75  60
LVVIs (mL/m2) 63  35 48  29 76  45 58  27 17  14 15  10 17  8 23  21
EF (%) 49  15 46  5 46  19 54  16 75  9 74  10 82  2.8 66  9
FS (%) 23  15 18  5 27  16 23  20 46  9 45  13 51  6 40  7
Values are expressed as mean  SD. LA/Ao, left atrial diameter/aortic diameter; LVVId, diastolic left ventricular volume index;
LVVIs, systolic left ventricular volume index; EF, ejection fraction; FS, fractional shortening MMVD, myxomatous mitral valve disease;
DCM, dilated cardiomyopathy; ISACHC, International Small Animal Cardiac Health Council.
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signiﬁcant diﬀerence for all categories of animals; the
log back-transformed regression equation is given in
Table 4. A multiple comparison test on the adjusted
means showed that plasma adiponectin concentration
was higher in dogs with DCM compared to healthy
dogs (P = .018) and to dogs with MMVD (P = .014),
whereas no signiﬁcant diﬀerence was seen between
dogs with MMVD compared to healthy dogs (Fig 4).
Pairwise ratios (DCM-healthy, DCM-MMVD,
MMVD-healthy) for the adjusted geometric means
and their 95% CI are given in Table 4. This table also
contains the Cohen’s d size eﬀects for diﬀerences that
are statistically signiﬁcant. From those numbers and
the standard of Cohen, DCM can be seen to have a
moderate to large eﬀect on plasma adiponectin concen-
tration. No signiﬁcant eﬀect of class of HF and no
interaction between disease and class of HF were
observed. No signiﬁcant relationship between echocar-
diographic indices (ejection fraction, fractional short-
ening, left atrial diameter/aortic diameter ratio, left
ventricular systolic volume index, left ventricular
Table 3. Analysis of covariance of plasma adiponec-
tin concentration (lg/mL). Adjusted geometric means
(admean) for the categorical eﬀect of intact and neu-
tered healthy dogs, ratios between the adjusted geo-
metric means of the neutered and intact dogs, Cohen’s
d eﬀect size between the neutered and intact dogs cal-







admean, intact 11.34 9.49 13.54
admean, neutered 7.10 5.36 9.41


























P = 0.2                                    P = 0.02
Fig 1. Box and whisker plots of plasma adiponectin concentra-
tion in healthy intact and neutered male and female dogs of dif-
ferent breeds. Medians are indicated by the midline; ﬁrst and
third quartiles by the open box; and minima and maxima by the




Fig 2. Average adiponectin reference values in units owing to
age for all healthy dogs (A), and separately for healthy intact
(B), and neutered (C) dogs as well as the 95% CI for the mean
of the predicted values.
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diastolic volume index), and plasma adiponectin con-
centration was found.
Discussion
This study demonstrates that plasma adiponectin is
negatively inﬂuenced by age and is lower in neutered
compared to intact dogs. No eﬀect of BCS and of BW
was observed. DCM in dogs (but not MMVD) is
associated with higher circulating adiponectin concen-
trations.
In humans, plasma adiponectin concentration is neg-
atively correlated with body fat content, and a low cir-
culating adiponectin concentration appears to be the
strongest predictor of metabolic syndrome.16 In dogs,
the implication of adiponectin in the pathogenesis of
obesity-related diseases is under investigation.17
Indeed, the physiology of adiponectin in dogs may dif-
fer from that in humans, and diseases associated in
humans with obesity such as type 2 diabetes mellitus
and atherosclerosis are uncommon in dogs.11 Some
studies showed low adiponectin concentrations in
obese dogs18,19 and lower adiponectin concentrations
in dogs with obesity-related metabolic dysfunction
compared to obese dogs without metabolic dysfunc-
tion20 as well as higher circulating adiponectin concen-
trations after a period of weight loss.21 On the other
hand, several studies have reported that, in dogs, per-
centage of body fat was not associated with adiponec-
tin concentration.22–27 Age, sex, and neuter status may
be confounding factors when studying the relationship
between adiposity and adiponectin.10 Discrepancies
also may be related to population diﬀerences or assay
type.20
Using a covariance analysis and previously men-
tioned variables, we found that circulating adiponectin
concentrations were dependent on age and neuter sta-
tus but not related to BW, BCS, or to sex. Neutering
was associated with a decrease in adiponectin
concentration, and the strength of this eﬀect was con-
sidered to be moderate to large. This ﬁnding is in con-
trast to 1 study with a small number of dogs (5
individuals per group) that showed a small and nonsig-
niﬁcant decrease in plasma adiponectin concentration
only in neutered males but not in neutered females10
















Time of day (h)
Fig 3. Plasma adiponectin concentration in 9 Beagles during a
24-hour period. Medians are indicated by the midline; ﬁrst and
third quartiles by the open box; and minima and maxima by the
lower and upper whiskers. Arrow represents the feeding time
(11 AM).
Table 4. Analysis of covariance of plasma adiponec-
tin concentration (lg/ml). Adjusted geometric means
(admean) for the categorical eﬀects of intact and neu-
tered healthy and heart failure dogs, ratios of the
adjusted geometric means between the diﬀerent cate-
gorical eﬀects and Cohen’s d size eﬀects between the







admean, intact 12.91 10.75 15.51
admean, neutered 6.56 4.98 8.63
Ratio neutered-intact 0.51 0.38 0.68
Cohen’s d neutered-intact 0.82 1.21 0.43
admean, DCM 13.95 9.70 20.05
admean, MMVD 7.04 4.95 10.01
admean, healthy 7.93 6.69 9.40
Ratio DCM—healthy 1.76 1.08 2.87
Ratio DCM—MMVD 1.98 1.12 3.51
Ratio MMVD—healthy 0.89 0.54 1.47
Cohen’s d DCM—healthy 0.76 0.23 1.29
Cohen’s d DCM—MMVD 0.86 0.19 1.52





















Fig 4. Plasma adiponectin concentration in healthy dogs, and
dogs with myxomatous mitral valve disease (MMVD) or dilated
cardiomyopathy (DCM). Medians are indicated by the midline;
ﬁrst and third quartiles by the open box; and minima and max-
ima by the lower and upper whiskers.
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adiponectin concentrations in 5 Beagle dogs at
3 months after surgery.28 In humans, adiponectin con-
centrations are higher in women than in men and this
diﬀerence is considered to be related to androgen con-
centrations.29,30 Our study supports a negative eﬀect of
neutering on circulating adiponectin concentrations
and a diﬀerence between dogs and humans in the role
of androgens on plasma adiponectin concentrations.
We also demonstrated that in dogs circulating adipo-
nectin concentrations decrease with age. This ﬁnding is
in accordance with a recent study in healthy adult cli-
ent-owned dogs showing that age was negatively asso-
ciated with adiponectin concentration.24 In our study,
although the age-neuter status interaction was non-sig-
niﬁcant, equations determined separately for neutered
and intact dogs suggest a possible more important
impact of age in neutered dogs compared to intact
dogs. In humans, circulating adiponectin concentra-
tions increase in the elderly.31 Adiponectin concentra-
tions also are greater in centenarians and their
oﬀspring32 and lower in healthy oﬀspring of patients
with essential hypertension33 suggesting that inherited
factors play a role in determining adiponectin concen-
trations. Several studies in humans have demonstrated
that circulating concentrations of adiponectin are
highly heritable, and genetic variants implicated in this
variability have been identiﬁed.34 In our study, plasma
adiponectin concentration was in the same range as
previously reported for humans6 and dogs.14 We also
observed wide variation in plasma adiponectin concen-
trations with absolute levels ranging from 1.6 to
18 lg/mL in control dogs. Additional studies are
needed to investigate the heritability and clinical rele-
vance of this variability.
In the substudy (including 9 dogs), we could not
ﬁnd any evidence of diurnal variation or an eﬀect of
feeding on circulating adiponectin concentrations.35
By including dogs with heart disease in the study,
we showed that plasma adiponectin concentrations
were higher in dogs with DCM compared to healthy
dogs and to dogs with MMVD. In human patients
with HF, plasma adiponectin concentrations are high
even after correction for body mass index.36,37 In these
studies, human patients were diagnosed with a disease
of the myocardium such as ischemic or nonischemic
dilated cardiomyopathy and hypertensive or primary
hypertrophic cardiomyopathy. These ﬁndings are in
accordance with our study, which showed that dogs
with primary myocardial disease have increased circu-
lating adiponectin concentrations. Our study showed
for the ﬁrst time that, in dogs, adiponectin concentra-
tions depend on the type of cardiac disease (primary
myocardial disease or endocardial disease). Indeed, in
dogs with MMVD, adiponectin concentration
remained in the reference range.
In humans, adiponectin concentration increases
with the severity of HF. High concentrations of
adiponectin are associated with mortality38 and treat-
ment and resolution of decompensated HF are
accompanied by a decrease in serum adiponectin con-
centration39–41 and a decrease in serum adiponectin
concentration in response to treatment predicts good
prognosis.42 In our study, circulating adiponectin
concentrations were not related to the severity of HF
as determined by ISACHC scale. This discrepancy
may be related to the small number of dogs in diﬀer-
ent severity classes leading to a lack of statistical
power.
The apparent paradox of adiponectin, a protein
known to be cardioprotective, being associated with
worse cardiovascular outcomes is referred to “reverse
epidemiology,” in which the risk factors for a disease
identiﬁed in a healthy population are unexpectedly
inversely associated with outcomes in a population
with the disease.9 The mechanisms behind the phenom-
enon for adiponectin and HF are still unknown. One
hypothesis is that adiponectin concentration is
increased in HF as a counter-regulatory protective
response but that unfortunately chronic increases in
adiponectin concentration lead to a decrease in adipo-
nectin receptors and functional resistance of adiponec-
tin in target tissues such as heart and muscles.37,39,43
This mechanistic hypothesis is supported in dogs by a
preliminary study showing an increase in myocardial
adiponectin concentration in HF suggesting a greater
production of adiponectin in the diseased myocar-
dium.b
A limitation of our study is that control dogs con-
sidered “healthy” did not undergo echocardiography.
Some of these dogs may have subclinical DCM with
no detectable abnormality on physical examination.
A second limitation is that the healthy group
included some severely underweight and overweight
dogs. Anamnesis and clinical examination did not
identify any systemic illness, but no other tests were
undertaken to explain the origin of the abnormal
BCS. Another limitation is that dogs groups were
not matched for physiologic parameters but the
impact of neuter status and age were taken into
account in the statistical analysis. In addition, the
small number of dogs in each class of HF and the
diﬀerence in the number of dogs among classes and
diseases may have resulted in an underpowered
analysis of the eﬀect of disease severity on plasma
adiponectin concentration. Finally, the majority of
the dogs were already under treatment for HF before
inclusion and some drugs may inﬂuence adiponectin
concentrations.44
Conclusions
In this study, plasma adiponectin concentration pro-
gressively decreased with age, and neutered animals
had lower concentrations than intact animals. Sex,
BW, BCS, circadian rhythm, and feeding did not inﬂu-
ence systemic adiponectin concentrations. Dilated car-
diomyopathy was associated with higher adiponectin
concentration compared to healthy and MMVD dogs,
and the strength of this eﬀect was considered moderate
to large. Additional research is required to investigate
if increased adiponectin concentrations may be a risk
factor for DCM.
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Footnotes
a Canine Adiponectin ELISA Kit; Millipore, St. Charles, MO
b Wood RM, Nelson OL, H€aggstr€om J, H€oglund K, Ljungvall I,
Kvart C. Adiponectin: a protective role in dogs with congestive
heart failure? Proceedings of the ACVIM Forum 2011:646 pp
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